Mismatch repair status predicts survival after adjuvant treatment in stage II colon cancer patients

医学 危险系数 内科学 结直肠癌 佐剂 阶段(地层学) 化疗 肿瘤科 癌症 辅助治疗 比例危险模型 置信区间 胃肠病学 古生物学 生物
作者
Ioannis Gkekas,Josef Novotný,Pavel Fabián,Radim Němeček,Richard Palmqvist,Karin Strigård,Stanislav John,Ladislav Pecen,Klaudia Reginacova,Ulf Gunnarsson
出处
期刊:Journal of Surgical Oncology [Wiley]
卷期号:121 (2): 392-401 被引量:9
标识
DOI:10.1002/jso.25798
摘要

Abstract Background and Objectives Stage II colon cancer is primarily a surgical disease. Only a still not well‐defined subset of patients may benefit from postoperative adjuvant chemotherapy. The relationship between adjuvant chemotherapy and survival after relapse is furthermore still not definitely explored in this group of patients. A number of reports suggest some association between defective mismatch repair (dMMR) and colorectal cancer stage II prognosis, but due to contradictory results from existing studies, the exact predictive role is still not fully understood. Methods Retrospective multicenter study including 451 stage II colon cancer patients. The proficiency or deficiency of mismatch repair was tested using immunohistochemistry and analyzed in relationship to two survival outcomes: overall survival (OS) and postrelapse survival. Results Patients with dMMR (20.4%) derived no OS benefit from adjuvant chemotherapy (hazard ratio [HR], 1.05; 95% confidence interval [CI], 0.47‐2.38; P = .897). Patients with proficient mismatch repair (pMMR) tumors receiving adjuvant chemotherapy had the significantly better OS in comparison to those not receiving chemotherapy (HR, 0.54; 95% CI, 0.35‐0.82; P = .004). This relationship remained significant in multivariable analysis (HR, 0.42; 95% CI, 0.22‐0.78; P = .007). Patients with pMMR relapsing after adjuvant treatment lived significantly longer than those relapsing without previous adjuvant treatment (HR, 0.55; 95% CI, 0.32‐0.96; P = .033) and this result remained significant in the multivariable model (HR, 0.49; 95% CI, 0.26‐0.93; P = .030). Conclusion In stage II CC patients, adjuvant chemotherapy improves therapeutic outcomes only in patients with pMMR tumors. Survival after relapse in patients having received adjuvant chemotherapy is significantly longer for patients with pMMR. No survival benefit from adjuvant chemotherapy was seen among patients with dMMR tumors.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
轻松幼南发布了新的文献求助30
刚刚
refraincc完成签到,获得积分10
刚刚
Lucas试剂发布了新的文献求助10
1秒前
HAHAHA完成签到,获得积分10
1秒前
Tzzl0226发布了新的文献求助10
2秒前
2秒前
2秒前
victor完成签到,获得积分10
2秒前
qianyu发布了新的文献求助10
3秒前
3秒前
乐空思举报zygclwl求助涉嫌违规
4秒前
就那样完成签到,获得积分10
5秒前
典雅猕猴桃完成签到,获得积分10
5秒前
cdercder应助性感锅包肉采纳,获得10
6秒前
亿眼万年完成签到,获得积分10
6秒前
烟花应助szmsnail采纳,获得10
6秒前
shuoshuo完成签到,获得积分20
6秒前
7秒前
稿它完成签到,获得积分10
7秒前
踏实的流沙完成签到 ,获得积分10
7秒前
molihuakai应助风趣小松鼠采纳,获得10
7秒前
7秒前
8秒前
圥忈完成签到,获得积分10
8秒前
70815发布了新的文献求助10
8秒前
9秒前
钟钟完成签到,获得积分10
10秒前
qianyu完成签到,获得积分10
10秒前
思政部完成签到 ,获得积分10
10秒前
11秒前
hehehaha发布了新的文献求助30
11秒前
小T儿发布了新的文献求助10
11秒前
12秒前
大模型应助标致的青梦采纳,获得10
12秒前
Akim应助shuoshuo采纳,获得10
13秒前
Troy北辰完成签到,获得积分10
14秒前
14秒前
15秒前
15秒前
紫色水晶之恋应助qianyu采纳,获得10
16秒前
高分求助中
Principles of Economics, 11th Edition 10000
University Physics with Modern Physics, 16th edition 10000
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Molecular Mechanisms of Photosynthesis, 4th Edition 1000
Organic Reactions, Volume 116 1000
Matrix Methods in Data Mining and Pattern Recognition 510
Social Skills Improvement System-Rating Scales--Chinese Version 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 内科学 物理 复合材料 催化作用 细胞生物学 无机化学 光电子学 物理化学 电极 基因
热门帖子
关注 科研通微信公众号,转发送积分 7254342
求助须知:如何正确求助?哪些是违规求助? 8876192
关于积分的说明 18741419
捐赠科研通 6934864
什么是DOI,文献DOI怎么找? 3200074
关于科研通互助平台的介绍 2374756
邀请新用户注册赠送积分活动 2174923